NCT02217020View on ClinicalTrials.gov

Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 15, 2014

Primary Completion Date

September 15, 2016

Study Completion Date

August 15, 2017

Conditions
Rectal Cancer
Interventions
DRUG

FOLFOXIRI

irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle

Trial Locations (1)

510655

Gastrointestinal Hospital, Sun Yatsen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02217020 - Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter